公开(公告)号：EP2356133A2

公开(公告)日：2011-08-17

申请号：EP09740089.9

申请日：2009-10-09

申请人： ERA Biotech, S.A.

发明人： RYBICKI, Edwar, Peter ,  MEYERS, Ann, Elizabeth ,  DEVESA, François ,  MARZÁBAL LUNA, Pablo ,  HITZEROTH, Inga, Isabel ,  ÖHLSCHLÄGER, Peter

IPC分类号： C07K14/025 ,  C07K14/425 ,  C12N15/62 ,  C07K14/16 ,  A61K39/00

CPC分类号： A61K39/21 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/385 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55516 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/005 ,  C07K14/415 ,  C07K14/425 ,  C07K2319/04 ,  C12N7/00 ,  C12N15/625 ,  C12N15/8216 ,  C12N15/8218 ,  C12N15/8257 ,  C12N15/8258 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16322

摘要： An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.